Prostac™ : Early, Precise and Non-Invasive Prostate Cancer Detection

Pre-FDA approved, Prostac™ is a patented, straightforward and non-invasive molecular-based blood test for the early, precise detection** of prostate cancer.  From blood drawn at the Doctor's office, Prostac™: ​

​

• Detects prostate cancer in men who have tested for higher PSA / Gleason scores.​

​​​

• Identifies a man's predisposition to developing prostate cancer.

​

• ​Categorizes the diagnosed prostate cancer into distinct risk groups ranging from indolent to aggressive castration-resistant.

​​

• Aids physicians in making better treatment decisions.

 
 
 
 
 
Men of African ancestry and men who have a family history of prostate cancer have a greater likelihood (i.e. a predisposition) of developing the disease.  Men in some work environments can also be 'at risk' for higher rates of prostate cancer.  Prostac™ can be used to test these men so that they know with confidence their likelihood of developing or not developing prostate cancer.  
​
Men with higher PSA / Gleason scores or who have a previous prostate cancer diagnosis can also use Prostac™ to verify a prostate cancer diagnosis.  Men testing negative with Prostac™ could then avoid the expensive, intrusive and often harmful screening tests, and even more expensive and potentially life-damaging overtreatments. 

 

Prostac™ can also test men for the progress and effectiveness of their treatments for prostate cancer.

Prostac™ takes away the worry and stress of an uncertain prostate cancer diagnosis and gives men the peace of mind and the confidence to take control of their personal health and well-being.   

** Note: In preliminary data analysis, Prostac™ is a better predictor of prostate cancer than PSA with better specificity, sensitivity and accuracy.